Digital’s potential to transform every aspect of the pharmaceutical value chain, from discovery to commercial, ...
£2,413.67
PharmaVitae explores and visualizes market dynamics in the Japan Pharma peer set out to 2027* ...
£2,417.70
Raxatrigine (Biogen) is a peripherally and centrally acting agent that inhibits sodium channels in a ...
£8,059.00
Nucynta (tapentadol; Collegium Pharmaceutical) first gained US Food and Drug Administration (FDA) approval in November ...
£8,059.00
Cebranopadol is a novel small molecule analgesic, which was discovered by Grünenthal. Cebranopadol represents a ...
£8,059.00
This Market Spotlight report covers the Erectile Dysfunction market, comprising key pipeline and marketed drugs, ...
£1,062.18
This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline ...
£1,062.18
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, ...
£1,062.18
Biogen’s chief medical officer says iPhone technology should in future be used for early warning ...
£80.59
This Market Spotlight report covers the Thyroid cancer market, comprising key pipeline and marketed drugs, ...
£1,062.18
This Market Spotlight report covers the Sjögren’s syndrome market, comprising key pipeline and marketed drugs, ...
£1,062.18
This Market Spotlight report covers the insomnia market, comprising key marketed and pipeline drugs, clinical ...
£1,062.18
This Market Spotlight report covers the irritable bowel syndrome (IBS) market, comprising key pipeline and ...
£1,062.18
This Market Spotlight report covers the Acne market, comprising key pipeline and marketed drugs, clinical ...
£1,062.18
This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, clinical trials, ...
£1,062.18
This Market Spotlight report covers the Hereditary Angioedema market, comprising key pipeline and marketed drugs, ...
£1,062.18
Zelboraf (vemurafenib; Roche/Chugai/Daiichi Sankyo) is an orally available agent that selectively targets the BRAF mutation. ...
£8,059.00
Tecentriq (atezolizumab; Roche/Chugai) is an antibody designed to target programmed death-ligand 1 (PD-L1) on tumor ...
£8,059.00
Tafinlar (dabrafenib; Novartis) is an adenosine triphosphate-competitive BRAF inhibitor with more than 100-fold selectivity for ...
£8,059.00
Opdivo is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the ...
£8,059.00
Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in ...
£8,059.00
Datamonitor interviewed an infectious diseases specialist based in the US Greater Washington DC area to ...
£482.73
Alzheimer's disease is an irreversible, progressive, neurodegenerative, and fatal disease that slowly affects memory, cognition, ...
£17,729.80
Binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase kinase ...
£8,059.00
Meningitis is an infection of the meninges, the membranes surrounding the brain and spinal cord. ...
£17,729.80
Sign up to the